UK Markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.62-0.51 (-5.59%)
At close: 04:00PM EDT
8.29 -0.33 (-3.83%)
After hours: 07:45PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.09
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 318.93
52-week low 37.40
50-day moving average 38.82
200-day moving average 311.92

Share statistics

Avg vol (3-month) 3664.04k
Avg vol (10-day) 3574.76k
Shares outstanding 553.46M
Implied shares outstanding 6N/A
Float 844.93M
% held by insiders 116.09%
% held by institutions 159.81%
Shares short (28 Apr 2022) 44.11M
Short ratio (28 Apr 2022) 46.16
Short % of float (28 Apr 2022) 410.88%
Short % of shares outstanding (28 Apr 2022) 47.68%
Shares short (prior month 30 Mar 2022) 44.09M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 315 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-386.85%

Management effectiveness

Return on assets (ttm)-21.49%
Return on equity (ttm)-37.12%

Income statement

Revenue (ttm)23.03M
Revenue per share (ttm)0.45
Quarterly revenue growth (yoy)-99.30%
Gross profit (ttm)-59.67M
EBITDA -88.83M
Net income avi to common (ttm)-88.44M
Diluted EPS (ttm)0.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)167.04M
Total cash per share (mrq)3.12
Total debt (mrq)3.67M
Total debt/equity (mrq)1.61
Current ratio (mrq)9.84
Book value per share (mrq)4.13

Cash flow statement

Operating cash flow (ttm)-60.09M
Levered free cash flow (ttm)-26.51M